JP2014527042A5 - - Google Patents

Download PDF

Info

Publication number
JP2014527042A5
JP2014527042A5 JP2014522877A JP2014522877A JP2014527042A5 JP 2014527042 A5 JP2014527042 A5 JP 2014527042A5 JP 2014522877 A JP2014522877 A JP 2014522877A JP 2014522877 A JP2014522877 A JP 2014522877A JP 2014527042 A5 JP2014527042 A5 JP 2014527042A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
acute lymphoblastic
hydrate
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014522877A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527042A (ja
JP6027110B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/047100 external-priority patent/WO2013016081A1/en
Publication of JP2014527042A publication Critical patent/JP2014527042A/ja
Publication of JP2014527042A5 publication Critical patent/JP2014527042A5/ja
Application granted granted Critical
Publication of JP6027110B2 publication Critical patent/JP6027110B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014522877A 2011-07-27 2012-07-18 ノッチ経路シグナリングインヒビター化合物 Active JP6027110B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161512016P 2011-07-27 2011-07-27
US61/512,016 2011-07-27
US201161560486P 2011-11-16 2011-11-16
US61/560,486 2011-11-16
PCT/US2012/047100 WO2013016081A1 (en) 2011-07-27 2012-07-18 Notch pathway signaling inhibitor compound

Publications (3)

Publication Number Publication Date
JP2014527042A JP2014527042A (ja) 2014-10-09
JP2014527042A5 true JP2014527042A5 (https=) 2015-08-20
JP6027110B2 JP6027110B2 (ja) 2016-11-16

Family

ID=46598983

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014522877A Active JP6027110B2 (ja) 2011-07-27 2012-07-18 ノッチ経路シグナリングインヒビター化合物

Country Status (36)

Country Link
US (1) US8569286B2 (https=)
EP (1) EP2736920B1 (https=)
JP (1) JP6027110B2 (https=)
KR (1) KR101578309B1 (https=)
CN (1) CN103732612B (https=)
AP (1) AP4080A (https=)
AR (1) AR087107A1 (https=)
AU (1) AU2012287251B2 (https=)
BR (1) BR112014001600B1 (https=)
CA (1) CA2841178C (https=)
CL (1) CL2014000175A1 (https=)
CO (1) CO6862159A2 (https=)
CR (1) CR20140036A (https=)
CY (1) CY1116645T1 (https=)
DK (1) DK2736920T3 (https=)
DO (1) DOP2014000011A (https=)
EA (1) EA023044B1 (https=)
EC (1) ECSP14013179A (https=)
ES (1) ES2544937T3 (https=)
GT (1) GT201400012A (https=)
HR (1) HRP20150771T1 (https=)
HU (1) HUE027534T2 (https=)
IL (1) IL229988A (https=)
JO (1) JO3148B1 (https=)
MA (1) MA35611B1 (https=)
ME (1) ME02171B (https=)
MX (1) MX356536B (https=)
MY (1) MY184303A (https=)
PE (1) PE20141061A1 (https=)
PH (1) PH12014500215B1 (https=)
PL (1) PL2736920T3 (https=)
PT (1) PT2736920E (https=)
RS (1) RS54135B1 (https=)
SI (1) SI2736920T1 (https=)
TW (1) TWI568730B (https=)
WO (1) WO2013016081A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110506A2 (en) * 2013-01-14 2014-07-17 The Trustees Of Columbia University In The City Of New York Methods of treating, preventing and diagnosing leukemia and other blood diseases and disorders
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
JO3491B1 (ar) * 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
IL287136B2 (en) 2016-02-05 2023-09-01 Denali Therapeutics Inc Receptor inhibitors - interacting with protein kinase 1
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
EP3442528B1 (en) * 2016-04-12 2021-05-26 Eli Lilly and Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating ovarian cancer
JP6911047B2 (ja) * 2016-04-12 2021-07-28 イーライ リリー アンド カンパニー がんの処置のための、Notch阻害剤およびCDK4/6阻害剤の併用療法
JP7194022B2 (ja) 2016-05-20 2022-12-21 イーライ リリー アンド カンパニー Notch阻害剤とPD-1またはPD-L1阻害剤との併用療法
SG11201901325UA (en) * 2016-08-31 2019-03-28 Lilly Co Eli Dosage regimen for treatment of solid tumors
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
JP7208137B2 (ja) 2016-12-09 2023-01-18 デナリ セラピューティクス インコーポレイテッド 化合物、組成物および方法
MX2019009552A (es) 2017-02-17 2019-10-02 Hutchinson Fred Cancer Res Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
MX2020004568A (es) * 2017-11-06 2020-10-05 Juno Therapeutics Inc Combinación de una terapia celular y un inhibidor de gamma secretasa.
KR20210005714A (ko) * 2018-05-06 2021-01-14 아얄라 파마큐티컬즈 아이엔씨. 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법
CA3114113A1 (en) 2018-10-02 2020-04-09 Frequency Therapeutics, Inc. Pharmaceutical compositions and methods related to otic therapeutic agents
US20220175776A1 (en) 2019-04-08 2022-06-09 Frequency Therapeutics, Inc. Combination of chir99021 and valproic acid for treating hearing loss
TW202334164A (zh) 2022-01-12 2023-09-01 美商戴納立製藥公司 (S)-5-苄基-N-(5-甲基-4-側氧基-2,3,4,5-四氫吡啶並[3,2-b][1,4]氧氮呯-3-基)-4H-1,2,4-三唑-3-甲醯胺的晶型

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001232A3 (en) * 1996-12-23 2001-02-28 Elan Pharmaceuticals Inc San F Cycloalkyl, lactam, lactone derivatives and their thio analogues inhibiting betha-amyloid peptide release and/or its synthesis and pharmaceutical compositions containing the compounds
JP2002518481A (ja) 1998-06-22 2002-06-25 エラン ファーマシューティカルズ,インコーポレイテッド β−アミロイドペプチドの放出および/またはその合成を阻害するための化合物
WO1999067221A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
EP1592684B1 (en) 2003-02-04 2008-07-30 F. Hoffmann-La Roche Ag Malonamide derivatives as gamma-secretase inhibitors
KR100838852B1 (ko) 2003-09-09 2008-06-16 에프. 호프만-라 로슈 아게 감마-세크리테이즈의 활성을 차단하는 말론아미드 유도체
SI1673347T1 (sl) 2003-10-06 2015-10-30 F. Hoffmann - La Roche Ag Substituirani derivati dibenzo-azepina in benzo-diazepina, ki so uporabni kot inhibitorji gama-sekretaze
ES2398531T3 (es) 2006-03-27 2013-03-20 F. Hoffmann-La Roche Ag Derivados de malonamida como inhibidores de gamma secretasa
KR101150574B1 (ko) * 2007-02-02 2012-05-30 에프. 호프만-라 로슈 아게 6-옥소-6,7-다이하이드로-5h-다이벤조[b,d]아제핀-7-일 유도체
MA33076B1 (fr) 2008-01-11 2012-03-01 Hoffmann La Roche Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
WO2011060051A1 (en) * 2009-11-12 2011-05-19 University Of Massachusetts Methods for treating glioblastoma

Similar Documents

Publication Publication Date Title
JP2014527042A5 (https=)
JP2020511467A5 (https=)
ME02171B (me) Spoj za inhibiciju notch signalnog puta
JP2013509429A5 (https=)
JP2015536964A5 (https=)
JP2014509653A5 (https=)
JP2017519027A5 (https=)
JP2014502638A5 (https=)
JP2013237682A5 (https=)
JP2015500331A5 (https=)
JP2013522326A5 (https=)
FI3328827T3 (fi) Glutamiinianalogien aihiolääkkeitä
JP2018024682A5 (https=)
JP2015509536A5 (https=)
JP2012255026A5 (https=)
JP2015508103A5 (https=)
HRP20171151T1 (hr) Inhibitori cdc7
JP2017525730A5 (https=)
JP2023542093A5 (https=)
HRP20202065T1 (hr) Kristalni oblik inhibitora mdm2
HRP20160545T1 (hr) Inhibitor fosfoinozitid 3-kinaze sa dijelom koji veže cink
JP2013522232A5 (https=)
JP2015522037A5 (https=)
JP2014530818A5 (https=)
JP2012526766A5 (https=)